scispace - formally typeset
M

Matthew S. Block

Researcher at Mayo Clinic

Publications -  127
Citations -  2918

Matthew S. Block is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 23, co-authored 108 publications receiving 2120 citations.

Papers
More filters
Journal ArticleDOI

Dose-Response Association of CD8(+) Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer

Ellen L. Goode, +112 more
- 01 Dec 2017 - 
TL;DR: This study demonstrates the histotype-specific nature of immune infiltration and provides definitive evidence for a dose-response relationship between CD8+ TILs and HGSOC survival and suggests that understanding factors that drive infiltration will be the key to unraveling outcome heterogeneity in this cancer.
Journal ArticleDOI

Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer

Hui Shen, +180 more
TL;DR: Different variants in HNF1B associate with risk of serous and clear cell epithelial ovarian cancer; DNA methylation and expression patterns are also notably distinct between these subtypes.
Journal ArticleDOI

Oncolytic Measles Virus Expressing the Sodium Iodide Symporter to Treat Drug-Resistant Ovarian Cancer

TL;DR: Immune monitoring posttreatment showed an increase in effector T cells recognizing the tumor antigens IGFBP2 and FRα, indicating that MV-NIS treatment triggered cellular immunity against the patients' tumor and suggesting that an immune mechanism mediating the observed antitumor effect was mediated.
Journal ArticleDOI

Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium

Rodabe N. Amaria, +97 more
- 01 Jul 2019 - 
TL;DR: The International Neoadjuvant Melanoma Consortium is established with experts in medical oncology, surgical oncologist, pathology, radiation oncologists, radiology, and translational research to develop recommendations for investigating neoadjuant therapy in melanoma to align future trial designs and correlative analyses.